Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy Options

Germ cell tumors are the most common malignancies in men under 50 years and also the most common cause of death from solid tumors in this age group. The past few decades have seen no change in the fact that 40% of such tumors have already metastasized by the time of initial diagnosis. In contrast to the majority of metastasized solid tumors, germ cell tumors can be effectively treated by cisplatin-based polychemotherapy. They only rarely show resistance mechanisms. Resistance to chemotherapeutics has been extensively examined in urological and nonurological tumors. Various mechanisms enabling malignant tumor cells to avoid the cytotoxic effect of chemotherapeutics have been discovered in the past few years. On the other hand, the reasons for the excellent responsiveness of germ cell tumors to chemotherapy have remained unclear. Theoretical models for the high cure rates of germ cell tumors after cisplatin-based polychemotherapy consider, on the one hand, molecular-biological aspects of malignant germ cell tumor cells per se and, on the other hand, the immunological and nonimmunological response mechanisms of the patients. This review article summarizes theoretical models for the high chemotherapy sensitivity of germ cell tumors and points out new therapeutic prospects.

[1]  K. Miller,et al.  The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours. , 2007, International journal of andrology.

[2]  J. Baselga,et al.  Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  W. Siegert,et al.  Activity of thalidomide in patients with platinum-refractory germ-cell tumours. , 2006, European journal of cancer.

[4]  M Mazumdar,et al.  Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Bray,et al.  Trends in testicular cancer incidence and mortality in 22 European countries: Continuing increases in incidence and declines in mortality , 2006, International journal of cancer.

[6]  J. Masters,et al.  Regulation of DNA repair gene expression in human cancer cell lines , 2006, Journal of cellular biochemistry.

[7]  W. Voigt,et al.  Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Groshen,et al.  Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. , 2006, Pharmacogenomics.

[9]  M. Spinella,et al.  A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma , 2005, Oncogene.

[10]  G. Rustin,et al.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.

[11]  H. Schmoll,et al.  Feasibility of a combination of high dose chemotherapy ifosfamide, carboplatin, etoposide (ICE) plus stem cells and bevacizumab in refractory sarcoma and germ cell tumors , 2005 .

[12]  G. Bepler,et al.  ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. , 2005, Chest.

[13]  J. Fleshman,et al.  Unfavourable expression of pharmacologic markers in mucinous colorectal cancer , 2005, British Journal of Cancer.

[14]  C. Dumontet,et al.  Chemoresistance in non-small cell lung cancer. , 2005, Current medicinal chemistry. Anti-cancer agents.

[15]  W. Siegert,et al.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Bokemeyer,et al.  Xeroderma Pigmentosum Group A Protein and Chemotherapy Resistance in Human Germ Cell Tumors , 2003, Laboratory Investigation.

[17]  J. Masters,et al.  Curing metastatic cancer: lessons from testicular germ-cell tumours , 2003, Nature Reviews Cancer.

[18]  J. Richie Role of P53 and MDM2 in treatment response of human germ cell tumors. , 2003, The Journal of urology.

[19]  S. Groshen,et al.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. , 2003, Clinical advances in hematology & oncology : H&O.

[20]  C. Bokemeyer,et al.  Molecular determinants of treatment response in human germ cell tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  A. Grothey,et al.  Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. , 2003, Cancer research.

[22]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Lippard,et al.  Testis-specific HMG-domain protein alters the responses of cells to cisplatin. , 2002, Journal of inorganic biochemistry.

[24]  J. Cairns Somatic stem cells and the kinetics of mutagenesis and carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Looijenga,et al.  Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. , 2002, Cancer research.

[26]  S. Lutzker,et al.  A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells , 2001, Oncogene.

[27]  K. Karplus,et al.  Nucleotide excision repair "a legacy of creativity". , 2001, Mutation research.

[28]  S. Chew,et al.  An exonic splicing silencer in the testes-specific DNA ligase III β exon , 2000 .

[29]  S. Chew,et al.  An exonic splicing silencer in the testes-specific DNA ligase III beta exon. , 2000, Nucleic acids research.

[30]  Paulus We Pharmacotherapy in pregnancy , 1999 .

[31]  M. Benahmed,et al.  Stem cell factor/c-kit system in spermatogenesis. , 1999, Human reproduction update.

[32]  R. Wood,et al.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.

[33]  C. Chresta,et al.  Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis , 1999, Oncogene.

[34]  W. Paulus [Pharmacotherapy in pregnancy]. , 1999, Therapeutische Umschau. Revue therapeutique.

[35]  D. D. de Rooij,et al.  The effect of 9-cis-retinoic acid on proliferation and differentiation of a spermatogonia and retinoid receptor gene expression in the vitamin A-deficient mouse testis. , 1998, Endocrinology.

[36]  D. D. de Rooij,et al.  Differential expression pattern of retinoid X receptors in adult murine testicular cells implies varying roles for these receptors in spermatogenesis. , 1998, Biology of reproduction.

[37]  D. D. de Rooij,et al.  Isolation and characterization of all‐trans‐retinoic acid–responsive genes in the rat testis , 1998, Molecular reproduction and development.

[38]  H. Gerhartz,et al.  The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. , 1998, Seminars in oncology.

[39]  P. Catalano,et al.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Braun Every sperm is sacred—or is it? , 1998, Nature Genetics.

[41]  R Sylvester,et al.  Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Lippard,et al.  Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. , 1998, Biochemistry.

[43]  S. Lippard,et al.  Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. , 1997, Biochemistry.

[44]  V. Torri,et al.  Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. , 1997, Gynecologic oncology.

[45]  H. Kampinga,et al.  Heat‐shock protein expression in cisplatin‐sensitive and ‐resistant human tumor cells , 1996, International journal of cancer.

[46]  A. Levine,et al.  A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation , 1996, Nature Medicine.

[47]  A. Hall,et al.  Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. , 1996, European journal of cancer.

[48]  L. Weber,et al.  Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. , 1996, Cancer research.

[49]  C. Chresta,et al.  Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.

[50]  J. Hickman,et al.  Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. , 1995, British Journal of Cancer.

[51]  L. Panasci,et al.  DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance. , 1995, Cancer letters.

[52]  N. Mulder,et al.  Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. , 1995, British Journal of Cancer.

[53]  M. Dym Spermatogonial stem cells of the testis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[55]  D. Lamb,et al.  Growth factors and testicular development. , 1993, The Journal of urology.

[56]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[57]  S. Nishikawa,et al.  Role of c-kit in mouse spermatogenesis: identification of spermatogonia as a specific site of c-kit expression and function. , 1991, Development.

[58]  L. Einhorn,et al.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Masters,et al.  Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. , 1990, Cancer research.

[60]  M. Green,et al.  Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. , 1988, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[61]  F. Friedlos,et al.  Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. , 1987, Cancer research.

[62]  P. Andrews,et al.  Effects of CIS‐platinum on embryonal carcinoma cell lines in vitro , 1984, International journal of cancer.

[63]  Rainer Frentzel-Beyme,et al.  Krebsatlas der Bundesrepublik Deutschland / Atlas of Cancer Mortality in the Federal Republic of Germany 1981–1990 , 1984 .

[64]  L. Einhorn,et al.  Improved chemotherapy in disseminated testicular cancer. , 1977, The Journal of urology.

[65]  C. Huckins The spermatogonial stem cell population in adult rats. I. Their morphology, proliferation and maturation , 1971, The Anatomical record.